Literature DB >> 21138199

Adoption of medications in substance abuse treatment: priorities and strategies of single state authorities.

Traci Rieckmann1, Anne E Kovas, Beth A Rutkowski.   

Abstract

Research has confirmed the effectiveness of medications, when used in conjunction with ongoing counseling, to treat substance abuse disorders. This article describes a national, mixed-methods research project designed to investigate single state authorities' (SSAs) perceptions of adoption of evidence-based practices in substance abuse treatment. Results are focused specifically on medication-assisted treatment, one of five evidence-based practices defined by the National Quality Forum. Medication-assisted treatment (MAT) is an important and effective part of comprehensive care options available to clients who are chronically ill with alcohol and other drug disorders. Despite mounting clinical evidence and increased availability, overall rates of implementation and sustained adoption of medications to treat addiction remain limited. The results illustrate that the SSA representatives who fund public treatment programs believe MAT is a priority and worthy of system-wide implementation. Current strategies utilized by SSAs to support the adoption of MAT are detailed, as are barriers to adoption and implementation.

Entities:  

Mesh:

Year:  2010        PMID: 21138199      PMCID: PMC3640346          DOI: 10.1080/02791072.2010.10400546

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  69 in total

Review 1.  Mortality and morbidity attributable to use of addictive substances in the United States.

Authors:  J M McGinnis; W H Foege
Journal:  Proc Assoc Am Physicians       Date:  1999 Mar-Apr

2.  A 3-year progress report on the implementation of LAAM in the United States.

Authors:  R A Rawson; A L Hasson; A M Huber; M J McCann; W Ling
Journal:  Addiction       Date:  1998-04       Impact factor: 6.526

3.  Buprenorphine for acute heroin detoxification: diffusion of research into practice.

Authors:  Anne E Kovas; Bentson H McFarland; Dennis J McCarty; Joshua F Boverman; James A Thayer
Journal:  J Subst Abuse Treat       Date:  2006-11-21

4.  Client and counselor attitudes toward the use of medications for treatment of opioid dependence.

Authors:  Traci Rieckmann; Marilyn Daley; Bret E Fuller; Cindy P Thomas; Dennis McCarty
Journal:  J Subst Abuse Treat       Date:  2006-12-08

5.  Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.

Authors:  P M Monti; D J Rohsenow; R M Swift; S B Gulliver; S M Colby; T I Mueller; R A Brown; A Gordon; D B Abrams; R S Niaura; M K Asher
Journal:  Alcohol Clin Exp Res       Date:  2001-11       Impact factor: 3.455

6.  Impact of substance disorders on medical expenditures for medicaid beneficiaries with behavioral health disorders.

Authors:  Robin E Clark; Mihail Samnaliev; Mark P McGovern
Journal:  Psychiatr Serv       Date:  2009-01       Impact factor: 3.084

7.  The underrecognized toll of prescription opioid abuse on young children.

Authors:  J Elise Bailey; Elizabeth Campagna; Richard C Dart
Journal:  Ann Emerg Med       Date:  2008-09-06       Impact factor: 5.721

8.  Buprenorphine versus methadone maintenance: a cost-effectiveness analysis.

Authors:  Christopher M Doran; Marian Shanahan; Richard P Mattick; Robert Ali; Jason White; James Bell
Journal:  Drug Alcohol Depend       Date:  2003-09-10       Impact factor: 4.492

9.  Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption.

Authors:  Lori J Ducharme; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2008-11-11

Review 10.  Research on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review.

Authors:  Bryan R Garner
Journal:  J Subst Abuse Treat       Date:  2008-11-12
View more
  11 in total

1.  Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study.

Authors:  Katherine J Karriker-Jaffe; Jianguang Ji; Jan Sundquist; Kenneth S Kendler; Kristina Sundquist
Journal:  Addiction       Date:  2017-05-16       Impact factor: 6.526

2.  Adoption and diffusion of evidence-based addiction medications in substance abuse treatment.

Authors:  Carolyn J Heinrich; Grant R Cummings
Journal:  Health Serv Res       Date:  2013-07-16       Impact factor: 3.402

3.  Improving treatment for opioid dependence: a perspective from the Ohio Valley node of the NIDA Clinical Trials Network.

Authors:  Erin L Winstanley; Greg S Brigham; Dean Babcock; Theresa Winhusen
Journal:  Prog Community Health Partnersh       Date:  2014

4.  Financial factors and the implementation of medications for treating opioid use disorders.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Addict Med       Date:  2012-12       Impact factor: 3.702

5.  The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2014-05       Impact factor: 2.582

6.  Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: Data from a national sample of treatment organizations.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  Subst Abus       Date:  2015-04-20       Impact factor: 3.716

7.  Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders.

Authors:  Hannah K Knudsen; Amanda J Abraham
Journal:  Psychiatr Serv       Date:  2012-01       Impact factor: 3.084

Review 8.  Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.

Authors:  Elizabeth M Oliva; Natalya C Maisel; Adam J Gordon; Alex H S Harris
Journal:  Curr Psychiatry Rep       Date:  2011-10       Impact factor: 5.285

9.  Establishing the feasibility of measuring performance in use of addiction pharmacotherapy.

Authors:  Cindy Parks Thomas; Deborah W Garnick; Constance M Horgan; Kay Miller; Alex H S Harris; Melissa M Rosen
Journal:  J Subst Abuse Treat       Date:  2013-03-13

10.  Views about responsibility for alcohol addiction and negative evaluations of naltrexone.

Authors:  Rebecca A Johnson; Jonathan M Lukens; Jonathan W Kole; Dominic A Sisti
Journal:  Subst Abuse Treat Prev Policy       Date:  2015-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.